No Data
Shanghai Shyndec Pharmaceutical Co., Ltd.'s (SHSE:600420) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Chinese Drug Regulator Denies Marketing of Shyndec Pharmaceutical's UTI Treatment Drug
Shanghai Shyndec Pharmaceutical (600420.SH): Wholly-owned subsidiary's Pharmaceutical has passed the consistency evaluation of generic drugs.
On December 30, Gelonghui reported that Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiaries, China National Pharmaceutical Group Wicked Pharmaceutical Co., Ltd. (referred to as Wicked) and China National Pharmaceutical Group Shantou Jinshi Pharmaceutical Co., Ltd. (referred to as Jinshi), respectively received the "Approval Notice for Pharmaceutical Supplementary Application" issued by the National Medical Products Administration.
Shanghai Shyndec Pharmaceutical (600420.SH) plans to have some Pharmaceuticals selected for the tenth batch of national centralized pharmaceutical procurement.
Shanghai Shyndec Pharmaceutical (600420.SH) announced that on December 12, 2024, the company and some of its subsidiaries...
Shanghai Shyndec Pharmaceutical (600420.SH): Plans to be selected for the 10th batch of national Pharmaceutical centralized procurement.
On December 13, Gelonghui reported that Shanghai Shyndec Pharmaceutical (600420.SH) announced that on December 12, 2024, the company and some of its subsidiaries participated in the bidding for the 10th batch of national centralized pharmaceutical procurement organized by the National Drug Procurement Office (referred to as the Unified Procurement Office), with some pharmaceuticals from its subsidiaries intended to be selected in this centralized procurement.
Shyndec Pharmaceutical Unit Gets Nod to Register Cefpodoxime Proxetil Tablets